Basics of particle therapy II biologic and dosimetric aspects of clinical hadron therapy.
Besides photons and electrons, high-energy particles like protons, neutrons, ⁴He ions or heavier ions (C, Ne, etc) have been finding increasing applications in the treatment of radioresistant tumors and tumors located near critical structures. The main difference between photons and hadrons is their different biologic effect and depth-dose distribution. Generally speaking, protons are superior in dosimetric aspects whereas neutrons have advantages in biologic effectiveness because of the high linear energy transfer. In 1946 Robert Wilson first published the physical advantages in dose distribution of ion particles for cancer therapy. Since that time hadronic radiotherapy has been intensively studied in physics laboratories worldwide and clinical application have gradually come to fruition. Hadron therapy was made possible by the advances in accelerator technology, which increases the particles' energy high enough to place them at any depth within the patient's body. As a follow-up to the previous article Introduction to Hadrons, this review discusses certain biologic and dosimetric aspects of using protons, neutrons, and heavy charged particles for radiation therapy.
Rong
Yi
Y
Department of Human Oncology, University of Wisconsin-Madison, USA.
Welsh
James
J
D004307:Dose-Response Relationship, Radiation; D005260:Female; D005544:Forecasting; D063193:Heavy Ion Radiotherapy; D006801:Humans; D018499:Linear Energy Transfer; D008297:Male; D009369:Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009502:Neutrons / Q000627:therapeutic use; D010315:Particle Accelerators; D017785:Photons / Q000627:therapeutic use; D061766:Proton Therapy; D011829:Radiation Dosage; D018787:Radiation Oncology / Q000379:methods / Q000639:trends; D011874:Radiometry; D011882:Radiotherapy, High-Energy / Q000379:methods*; D016019:Survival Analysis; D016896:Treatment Outcome; D011522:Protons
D011522:Protons